Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) have been given an average recommendation of “Hold” by the nine ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) Director Johan Wedell-Wedellsborg purchased 62,516 shares of the stock in a transaction that occurred on Monday, November 27th. The shares were purchased at an average price of $5.49 per share, with a total value of $343,212.84. Following the completion of the acquisition, the director now directly owns […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, August 10th. Analysts expect Y-mAbs Therapeutics to post earnings of ($0.24) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link. Y-mAbs […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given an average rating of “Hold” by the eleven brokerages that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average […]
Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Given Consensus Recommendation of Hold by Brokerages themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.